MedTrace Logo

Donor Simvastatin Treatment in Organ Transplantation

NCT01160978 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2017-09-19

No results posted yet for this study

Summary

The aim of the study is to investigate the effects of donor simvastatin treatment on ischemia-reperfusion injury after heart transplantation.

Conditions

Interventions

DRUG

Simvastatin 80mg

The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.

DRUG

Control Rx

The transplant recipients who have received an organ from non-treated donors.

Sponsors & Collaborators

  • University of Helsinki

    collaborator OTHER

  • Academy of Finland

    collaborator OTHER

  • Helsinki University Central Hospital

    lead OTHER

Principal Investigators

  • Karl B Lemstrom, MD, PhD · Cardiac surgery, Heart and Lung Center, Helsinki University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-01
Primary Completion
2016-08-01
Completion
2016-08-01

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01160978 on ClinicalTrials.gov